Ewa Gatlik

DFV890: a new oral NLRP3 inhibitor—tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function

Ildikó Madurka, Alexander Vishnevsky, Joan B. Soriano et al. · Infection · 2022 · 77 citations · Full text

New Oral Nlrp3, Early Phase 2A, Antiviral Therapy +4

First‐in‐human safety, tolerability, and pharmacokinetic results of DFV890, an oral low‐molecular‐weight NLRP3 inhibitor

Ewa Gatlik, Beata Mehes, Emilie Voltz et al. · Clinical and Translational Science · 2024 · 45 citations · Full text

Midostaurin, a Novel Protein Kinase Inhibitor for the Treatment of Acute Myelogenous Leukemia: Insights from Human Absorption, Metabolism, and Excretion Studies of a BDDCS II Drug

Handan He, Phi Tran, Helen Gu et al. · Drug Metabolism and Disposition · 2017 · 43 citations

Plasma Protein Binding of Highly Bound Drugs Determined With Equilibrium Gel Filtration of Nonradiolabeled Compounds and LC-MS/MS Detection

John Isbell, Ding Yuan, Leonel Torrão et al. · Journal of Pharmaceutical Sciences · 2018 · 24 citations

Equilibrium Gel Filtration to Measure Plasma Protein Binding of Very Highly Bound Drugs

H. Weiss, Ewa Gatlik · Journal of Pharmaceutical Sciences · 2013 · 15 citations

Protein Chemistry, Drug Target, Biochemistry +10